3. What Is SAS?
SAS-Statistical analysis software/System
Developed in the early 1970s at North Carolina
State University.
Originally intended for management and analysis of
agricultural field experiments.
Now the most widely used statistical software
CEO-Jim Gudnight (Founder of SAS institute)
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
4. What Is a Clinical Trial?
Effectiveness of intervention to treat a
disease
Safety of a new drug or device
Defining dose administration
Testing drug formulation
Exploring combination therapies
Evaluating effect of therapies on quality of
life
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
5. Clinical Research Process
Approved protocol Investigator selection Approval Process
Patient
Recruitment
Data Entry & ValidationData
Analysis
Presentation to Steering committee Submission for FDA/DCGI
6. Types of Clinical Trials
Treatment
– Test new approaches to treat a disease
Prevention
– What approaches can prevent disease
Early-detection/screening
– What are new ways to find hidden disease
Diagnostic
– How can new tests or procedures ID disease
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
7. Clinical Trails – Overview
Chemistry
Synthesis Purification
Formulation
Animal
Pharmacology
Animal Toxicity
Asses Safety &
Biological activity in
Animals
PHASE – I
Determine
Safety &
Dosage
PHASE – II
Evaluate
Efficacy, look
for side
effects
PHASE- III
Compare new
agent with
standard
treatment
Safety
FDA /
DCGI
PHASE IV
Additional
post
marketing
testing
required by
FDA
Pre-clinical Development Clinical Trails
Accelerated Development / Review
IND
5000 compounds
evaluated
5 enter trails 1 approved – SUCCESS RATE
File IND at
FDA / DCGI
File NDA at
FDA / DCGI
3-4 YEARS 6 YEARS 2 YEARS
8. Phases of Drug Development
Phase 1 Phase 2 Phase 3 Phase 4
No. of
Participants
15-30 100-300 100 to
thousands
Several
hundreds to
several
thousands
Purpose First in
humans
safe dose
POC
1/3 fail
Determine
efficacy
Safety
50% fail
Compare
new agent
with standard
treatment
Safety
1/3 fail
Post –market
Long-term
safety and
efficacy
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
9. Who are the Players?
Human Subject Volunteers
Physician Investigators & Staff
NIH – National Institutes for Health
Manufacturing companies (Sponsor)
OHRP - Office for Human Research Protections
FDA – Food & Drug Administration (CDER, CBER, CDRH)
Settings: Academic, Private Practice, Professional
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
10. Why is Human Research Highly
Regulated?
Past transgressions lead to the need for laws
that protect the rights and welfare of human
subjects.
– Nuremberg Doctors Trial of 1946 (Nuremberg Code)
– Thalidomide Tragedy (Kefauver-Harris Amendment)
– Tuskegee Experiments (Belmont Report)
– Human Radiation Experiments
– Gene Transfer Experiment
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
11. Evolution of Regulations
1938 – Food, Drug & Cosmetic ACT
1962 – Kefauver-Harris Amendment
1968 – Drug Efficacy Study Implementation
1981 – IRB Review Required
1983 – Orphan Drug Act
1997 – ICH-E6 Good Clinical Practice (GCP)
1998 – Pediatric Rule
2000 – NIH launches www.clinicaltrials.gov
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
12. Declaration of Helsinki
World Medical Association June 1964
(Helsinki, Finland)
Forms the basis of ICH-GCP
Covers all “medical research”
Most recent amendment October 2000
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
13. Human Research is Highly
Regulated
Code of Federal Regulations (CFR)
– Title 21- Food and Drugs
» Part 50 Informed Consent
» Part 56 IRB
» Part 312 IND
» Part 314 NDA
» Part 600, 6001 Biologics
» Part 812, 813, 814 Medical Devices
– Title 45- Public Welfare
» Part 46 (subparts B, C, D) DHHS, Protection of Human subjects
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
14. What About International
Regulation?
ICH definition – GCP
“A standard for the design, conduct, performance,
monitoring, auditing, recording, analyses, and
reporting of clinical trials that provides assurance
that the data and reported results are credible and
accurate, and that the rights, integrity, and
confidentiality of trial subjects are protected”
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
15. ICH-GCP
ICH is the International Conference on
Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for
Human Use
ICH-GCP is Good Clinical Practice
guidelines agreed at the conference
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
16. The Objectives of ICH GCP
Guidelines
Developed with consideration of the current good clinical
practices of the European Union, Japan & USA, plus those of
Australia, Canada, the Nordic countries & World Health
Organisation.
Provide a unified standard for the European Union, Japan &
USA to facilitate the mutual acceptance of clinical data by the
regulatory authorities in these jurisdictions.
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
17. Good Clinical Practice - GCP
What is GCP?
– Ethical and scientific quality standards for
designing, conducting, recording and reporting
trials that involve participation of human
subjects
Why is it needed?
– To ensure that the RIGHTS, SAFETY and
WELLBEING of the trial subjects are protected
– Ensure the CREDIBILITY of clinical trial data
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
19. Research Protocol: Roadmap
Detailed Research Plan that Includes:
– Objectives
– Background and Rationale
– Subject Selection Criteria
– Treatment Plan
– Study Procedures
– Response Evaluation Criteria
– Statistical Section
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
20. Protocols
A Phase I, Double-blind, Placebo-
controlled, Dose-escalation Study of the
Safety and Pharmacokinetics of Drug A31
in Subjects with Type 2 Diabetes Mellitus
A randomized, double-blind, placebo-
controlled study assessing the effect of
(study drug) Controlled-Release Tablet on
hypoglycemia in type 1 diabetic subjects
intensively treated with insulin
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
21. Protocol Mouthful
A PHASE 1, RANDOMIZED, PLACEBO-
CONTROLLED, SEQUENTIAL PARALLEL
GROUP, MULTIPLE DOSE ESCALATION
TRIAL TO EVALUATE THE SAFETY,
TOLERABILITY, PHARMACOKINETICS,
AND PHARMACODYNAMICS OF 28 DAYS
OF ADMINISTRATION OF ND- 00254
TABLETS TO SUBJECTS WITH TYPE 2
DIABETES MELLITUS
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
24. Institutional Review Board
(IRB)
All clinical trials must be approved and
monitored by an IRB.
IRB is an independent committee of
physicians, nurses, statisticians, community
advocates and others.
The function of the IRB is to ensure that a
clinical trial is ethical and the rights welfare
of study participants are protected.
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
25. What is Informed Consent?
"Informed consent is a process by which a subject
voluntarily confirms his or her willingness to
participate in a particular clinical trial, after having
been informed of all aspects of the trial that are
relevant to the subject's decision to participate”
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
26. Informed Consent
Learning the key facts about a trial before
deciding whether to participate.
– Research study purpose
– Risks/Benefits
– Alternative treatments
– Confidentiality of records
– Medical treatment available if injury occurs
– Whom to contact for answers to questions
– Statement that participation is voluntary
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
27. Patient Recruitment Challenge
Poor patient recruitment is the number one
reason that trials fail.
Only 3 to 5 percent of newly diagnosed
adult cancer patients participate in a clinical
trial.
Reasons for this relatively low number are
many.
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
28. Recruitment Strategies
Physician trust and contact
Study staff contact
Speaking to community groups
Newspaper and radio Ads
Internet websites
Physician referrals
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
29. Safety Data collected in Clinical
Trials
Adverse Events
Serious Adverse Events
Adverse Reactions
Suspected Unexpected Serious Adverse
Reaction
Pregnancy
Lab data
Vital Signs
Project specific data
30. Safety Data collected in Clinical
Trials
Data is collected on case report forms
(CRF)
Much of clinical data is taken from the
subjects medical record (source documents)
Pharmaceutical and device trials, data is
verified by multiple players
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
31. Done in excel using a blank CRF template provided by
Openclinica
Designing CRFs
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
39. Backups implemented via a scheduled command
running as a batch file that writes out the data and
metadata for each of the studies databases adding
Timestamp information to the filename.
Pg Dump utility Creates a backup file on
the secondary HDD on the main server.
File automatically copied to NAS1
NAS1
DatabaseDatabase
server
The Back Up Setting
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
40. Clinical Data Management
Protocol CRF Design DB Design
DB
Validation
DatabaseReport Data Analysis
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
41. Data Analysis
Database Extraction SAS Tables
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
42. An Adverse Event (AE) is…
Any untoward medical occurrence
Not necessarily causal relationship with
treatment
Unfavourable /unintended sign
43. A Serious Adverse Event (SAE) is an AE that…
Results in death
Is life threatening
Requires hospitalisation or prolongation of
stay
Results in persistent or significant
disability/incapacity
44. SAE definitions
Results in death
– Record the event that lead to death as the SAE
– “Death” is the outcome
Life threatening
– “The patient was, in the view of the
investigator, at immediate risk of death from
the event as it occurred. It does not include an
event that, had it occurred in a more serious
form, might have caused death”
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
45. SAE definitions
Prolonged hospitalisation
- Record diagnosis NOT procedure
- Hospitalisation means in-patient
admission
- Not out-patient appointments or ED
visits
Disabling or incapacitating
- Event which is disabling or
46. SAE definitions
Prolonged hospitalisation
– Record diagnosis NOT procedure
– Hospitalisation means in-patient admission
– Not out-patient appointments or ED visits
Disabling or incapacitating
– Event which is disabling or incapacitating or
causes a disruption of one’s ability to carry out
normal life functions or daily activitiesContact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
47. SAE definitions
Congenital anomaly
– Diagnosed in the offspring of a subject who
received study drug
Other
– Additional option given by some
pharmaceutical companies
– Event not covered by SAE categories but in the
investigator’s opinion, should be considered
serious
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
48. A Suspected Adverse Reaction (SAR)
is…
Untoward or unintended response to the
medicinal product under investigation
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
49. A Suspected Unexpected Serious Adverse Reaction
(SUSAR) is…
A serious adverse reaction
Unexpected-not consistent with information
already available in the protocol and the
Investigators Brochure
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
50. Adverse event reporting
Will depend upon the trial and be defined in the
protocol
Generally any AE or SAR should be recorded in the
patient notes and Case Report Form and reported to
the Principal Investigator (PI) at the study site
The PI determines whether the AE or SAR is serious
The PI informs the Chief Investigator (multicentre
studies) of any SAE or SUSAR
The Chief Investigator will report any SAE or SUSAR
to the Trial Sponsor, Data Monitoring Committee,
MHRA and/or Ethics Committee, as specified in the
protocol
51. Introduction to MedDRA
(Medical Dictionary
for Regulatory Activities)
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
52. What is MedDRA?
Med = Medical
D = Dictionary for
R = Regulatory
A = Activities
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
53. Objectives for MedDRA Development
An international multi-lingual terminology
Standardized communication between
industry and regulators
Support of electronic submissions
Application through all phases of the
development cycle
To provide:
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
54. Objectives for MedDRA Development
(cont)
Classification for a wide range of clinical
information
Support for multiple medical product areas
A terminology that saves time, resources,
and money
To provide (cont):
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
55. MedDRA Definition
MedDRA is a clinically-validated international
medical terminology used by regulatory
authorities and the regulated biopharmaceutical
industry. The terminology is used through the
entire regulatory process, from pre-marketing
to post-marketing, and for data entry, retrieval,
evaluation, and presentation.
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
56. MedDRA Hierarchy
System Organ Class (SOC)
High Level Group Term (HLGT)
High Level Term (HLT)
Preferred Term (PT)
Lowest Level Term (LLT)
57. System Organ Classes
• Blood and lymphatic system disorders
• Cardiac disorders
• Congenital, familial and genetic disorders
• Ear and labyrinth disorders
• Endocrine disorders
• Eye disorders
• Gastrointestinal disorders
• General disorders and administration site
conditions
• Hepatobiliary disorders
• Immune system disorders
• Infections and infestations
• Injury, poisoning and procedural
complications
• Investigations
• Metabolism and nutrition disorders
• Musculoskeletal and connective tissue
disorders
• Neoplasms benign, malignant and unspecified
(incl cysts and polyps)
• Nervous system disorders
• Pregnancy, puerperium and perinatal
conditions
• Psychiatric disorders
• Renal and urinary disorders
• Reproductive system and breast disorders
• Respiratory, thoracic and mediastinal disorders
• Skin and subcutaneous tissue disorders
• Social circumstances
• Surgical and medical procedures
• Vascular disorders
58. Each MedDRA term assigned an 8-digit
numeric code
The code is non-expressive
Codes can fulfill a data field in various
electronic submission types (e.g., E2b)
Initially assigned alphabetically by term
starting with 10000001
– New terms are assigned sequentially
Supplemental terms are assigned codes
MedDRA Codes
59. Terms are being renamed
– When terms are renamed, the code number is
reused for the renamed term
– Renaming has been done for spelling errors,
hyphenation, and parenthesis changes
When HLT or HLGT terms are removed from
the terminology, they are deleted – NOT
moved to the LLT level and made non-current
MedDRA Codes (cont)
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
60. Non-Current Terms
Non-current terms are flagged at the LLT
level within MedDRA
Not recommended for continued use
Retained within the terminology to preserve
historical data for retrieval and analysis
Terms very vague, ambiguous, out-dated,
truncated, or misspelled
Terms derived from other terminologies that
do not fit MedDRA rules
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
61. A Multi-Axial Terminology
Multi-axial = the representation of a medical
concept in multiple SOCs
Allows terms to be grouped by different
classifications
Allows retrieval and presentation via
different data sets
Allows an automatic assignment of
predefined term groupings
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
64. What’s New for MedDRA
Version 15.1
MedDRA Version 15.1 was made available
to subscribers on 1 September 2012
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
65. Clinical Trial End Product
Ideal: Unambiguous conclusion regarding
the clinical outcome of the test
treatment/device.
Always strive for the ideal, but in most
cases have to settle for the best comprise.
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
67. Today’s Assignment
Visit www.sas.com to know more about SAS
Contact : Balu India : +91-9966956770 +91-9966946199 USA: +1 (551) 226-6061
www.sasonlinetrainings.com E-mail : contact@sasonlinetrainings.com
68. Please Visit……
www.sasonlinetrainings.com
Address :
SAS onlineTraining Center
Near Cyber Towers, Hitech City
Hyderabad. Pin -500081
Andhra Pradesh, India.
E mail : contact@sasonlinetrainings.com
India : +91-9966956770
+91-9966946199
USA: +1 (551) 226-6061
Skype : appalanaidu412